BLEOMYCIN FOR INJECTION DIN 02566346
Status: Approved
Holder: MARCAN PHARMACEUTICALS INC
Molecule: BLEOMYCIN (BLEOMYCIN SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous; Intrapleural; Intravenous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01DC01 BLEOMYCIN |
| Original market date | |
| Current status date | 03-Mar-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Marcan Pharmaceuticals Inc. — licence 101909, currently licensed, last inspection rating C (2024-05-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BLEOMYCIN (BLEOMYCIN SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02265982 | BLEOMYCIN FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Marketed |
| 02131692 | BLEOMYCIN FOR INJECTION USP | PFIZER CANADA ULC | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Marketed |
| 02367351 | BLEOMYCIN FOR INJECTION USP | SANDOZ CANADA INCORPORATED | Powder For Solution | BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37036 | 2026-03-03 | Abbreviated New Drug Submission (ANDS) |